Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | IDO1 | P14902 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623866 | 0.91 | LTA4H (0.67) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL9151562 | 0.89 | ALDH1A1 (0.61) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL10466462 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL1254211 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL11437812 | 0.85 | ALDH1A1 (0.68) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL8158206 | 0.83 | SMN1; SMN2 (0.55) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL9486112 | 0.83 | ALDH1A1 (0.55) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL190915 | 0.83 | ALDH1A1 (0.65) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL3933929 | 0.83 | ALDH1A1 (0.65) | ALDH1A1ALOX15TP53CYP3A4TSHR | |
| SCHEMBL6079570 | 0.82 | ALDH1A1 (0.53) | ALDH1A1ALOX15TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246931-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | HOSPIRA, INC. (US) | 2015-09-03 | — | — | US | claimed |
| EP-2892903-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2015-07-15 | — | — | EP | claimed |
| WO-2014037893-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2014-03-13 | — | — | WO | claimed |
| EP-1594505-A4 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | claimed |
| US-7122559-B2 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | claimed |
| EP-1594505-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | claimed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | claimed |
| EP-0421440-B1 | Process for producing azetidinone derivatives | MERCIAN CORP (JP) | 1997-05-28 | — | — | EP | claimed |
| EP-0331146-B1 | Process for preparation of beta-lactam derivatives | OTSUKA KAGAKU KK (JP) | 1994-01-12 | — | — | EP | claimed |
| US-5149802-A | Chemical intermediates for antibiotics | MERCIAN CORPORATION (JP) | 1992-09-22 | — | — | US | claimed |
| US-5053500-A | INTERMEDIATES FOR THE PREPARATION OF BETA-LACTAM ANTIBIOTICS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | claimed |
| US-4925934-A | DEESTERIFICATION | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-05-15 | — | — | US | claimed |
| EP-0331146-A1 | Process for preparation of beta-lactam derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1989-09-06 | — | — | EP | claimed |
| WO-1988001619-A1 | 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-10 | — | — | WO | claimed |
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | claimed |
| US-4556514-A | INTERMEDIATES FOR PRODUCTION OF CARBAPENEM OR PENEM DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-03 | — | — | US | claimed |
| EP-0106652-A1 | Beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | claimed |
| JP-8325281-A | — | — | None | — | — | JP | disclosed |
| US-20150246931-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | HOSPIRA, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2892903-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2015-07-15 | — | — | EP | disclosed |
| US-8742124-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2014-06-03 | — | — | US | disclosed |
| WO-2014037893-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2014-03-13 | — | — | WO | disclosed |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | disclosed |
| EP-2396314-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-7943776-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7786115-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-08-31 | — | — | US | disclosed |
| WO-2010092387-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| WO-2009138778-A1 | CYCLOPROPYL BENZAMIDE DERIVATIVES AS INTERMEDIATES FOR CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138777-A1 | PROCESS FOR THE PREPARATION OF ALKOXY-PHENOXY-PI PERIDINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-2078000-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2009-07-15 | — | — | EP | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-2027113-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20090018157-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20080234273-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1594505-A4 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-20080146566-A1 | Amide Derivatives | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1928874-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008050117-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1915350-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1910350-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1856062-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| EP-1831174-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1802582-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME. | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-7230108-B2 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB | 2007-05-17 | — | — | US | disclosed |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB | 2007-04-26 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-7199140-B2 | Vinyl phenyl derivatives as GLK activators | ASTRAZENECA AB (SE) | 2007-04-03 | — | — | US | disclosed |
| WO-2007031739-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007020411-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007042-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718298-A2 | PROCESS FOR MAKING EP4 AGONISTS AND INTERMEDIATES THEREOF | Merck & Co., Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| US-7122559-B2 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1699766-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1697324-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1697325-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| US-7101897-B2 | Farnesyl transferase inhibitors | ASTRAZENECA AB (SE) | 2006-09-05 | — | — | US | disclosed |
| WO-2006090143-A1 | 4-0X0QUINAZ0LIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
| EP-1695705-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1689741-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE ACTIVATORS | AstraZeneca AB (SE) | 2006-08-16 | — | — | EP | disclosed |
| US-20060173177-A1 | Process for preparation of penam derivatives | HELM AG (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1686131-A2 | Process for preparation of penam derivatives | Helm AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682509-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006067444-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-7037907-B1 | Estradiol conjugates and uses thereof | THE UNIVERSITY OF MELBOURNE (AU) | 2006-05-02 | — | — | US | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1112284-B1 | PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| EP-1255733-B1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| EP-1594505-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1583532-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | Astrazeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050209217-A1 | 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors | BOYLE FRANCIS T | 2005-09-22 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-6946468-B1 | 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors | ZENECA LIMITED (GB) | 2005-09-20 | — | — | US | disclosed |
| WO-2005079337-A2 | PROCESS FOR MAKING EP4 AGONISTS AND INTERMEDIATES THEREOF | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005061465-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005056530-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005054200-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054233-A1 | BENZOYL AMINO PYRIDIL CARBOXYLIC ACID DERIVATIVES AS GLUOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005044801-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-6784174-B1 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TNF | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-6777438-B2 | TREATING A DISEASE OR MEDICAL CONDITION MEDIATED THROUGH FARNESYLATION OF RAS BY FARNESYL TRANSFERASE | ASTRAZENECA AB (SE) | 2004-08-17 | — | — | US | disclosed |
| WO-2004065411-A2 | PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6770627-B1 | Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p 53 | ASTRAZENECA AB (SE) | 2004-08-03 | — | — | US | disclosed |
| US-20040138104-A1 | Peptides | THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, | 2004-07-15 | — | — | US | disclosed |
| WO-2004045614-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1406620-A1 | VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS | Astrazeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1404335-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | Astrazeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-6716847-B2 | ANTIALLERGENS, ANTIINFLAMMATORY | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-20030216417-A1 | Substituted anilino-quinoline compounds and use thereof | ASTRAZENECA AB | 2003-11-20 | — | — | US | disclosed |
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-20030186966-A1 | Amide derivatives | ASTRAZENECA AB | 2003-10-02 | — | — | US | disclosed |
| US-6620972-B2 | Fluorous sulfoxides used to oxidize primary or secondary alcohols to aldehydes or ketones in presence of activator, followed by treatment with organic base | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-09-16 | — | — | US | disclosed |
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| EP-1165566-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6593333-B1 | Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB | 2003-06-05 | — | — | US | disclosed |
| US-20030096842-A1 | Inhibitors of farnesyl protein transferase | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | US | disclosed |
| US-20030083348-A1 | Farnesyl transferase inhibitors | EIGER BIOPHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6552223-B1 | Metalloproteinase enzyme inhibitors | ASTRAZENECA AB (SE) | 2003-04-22 | — | — | US | disclosed |
| US-6548514-B1 | Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | disclosed |
| US-6541491-B1 | Treating ras mediated diseases, especially cancer. | ZENECA LIMITED (GB) | 2003-04-01 | — | — | US | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| WO-2003002526-A1 | METHOD OF OXIDIZING AN ALCOHOL USING A RECYCLABLE FLUOROUS SULFOXIDE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003000262-A1 | VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| US-6495551-B1 | P-IMIDAZOLE-PHENYL-OXAZOLIDINES; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | SYNGENTA LIMITED (GB) | 2002-12-17 | — | — | US | disclosed |
| US-6486156-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-11-26 | — | — | US | disclosed |
| EP-1255733-A1 | FARNESYL TRANSFERASE INHIBITORS | AstraZeneca AB (SE) | 2002-11-13 | — | — | EP | disclosed |
| US-6465455-B1 | TUMOUR NECROSIS FACTOR AND INTERLEUKIN FAMILY INHIBITORS; INHIBITION OF ENZYME P38 KINASE; INFLAMMATION, IMMUNO-REGULATION, ALLERGIES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1242372-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| US-6417183-B1 | DRUGS RELATES TO 1,4-DIAZACYCLOHEPTANES, TO PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND TO THEIR USE IN METHODS OF THERAPEUTIC TREATMENT OF NERVOUS SYSTEM DISORDERS | ASTRAZENELA UK LIMITED (GB) | 2002-07-09 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6410539-B1 | ANTICARCINOGENIC AGENTS | ASTRAZENCA UK LIMITED (GB) | 2002-06-25 | — | — | US | disclosed |
| US-6407093-B1 | (3,4-DIHYDRO-2H-BENZOTHIOPYRAN-4-YL)-HOMOPIPERAZINE DERIVATIVES; ANTIISCHEMIC AGENTS; ALZHEIMER*S AND PARKINSON*S DISEASE, AIDS RELATED DEMENTIA, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS | ASTRAZENECA UK LIMITED (GB) | 2002-06-18 | — | — | US | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | ZENECA LIMITED | 2002-04-04 | — | — | US | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| US-6350775-B1 | AGAINST GRAMPOSITIVE BACTERIA | ZENECA LIMITED (GB) | 2002-02-26 | — | — | US | disclosed |
| EP-1165566-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | AstraZeneca AB (SE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| EP-1140858-A2 | ARYLPROPENYLIMIDAZOLES AS FARNESYL-PROTEIN TRANSFERASE INHIBITORS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1117653-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| EP-1112284-A1 | PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | AstraZeneca AB (SE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001046138-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046137-A1 | FARNESYL TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1109777-A1 | N-HYDROXYACYLAMINO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| US-6242615-B1 | AMIDATION OF ACID CONTAINING COMPOUNDS; USEFUL IN INHIBITING TUMOR NECROSIS FACTOR AND METALLOPROTEINASES | ZENECA LIMITED (GB) | 2001-06-05 | — | — | US | disclosed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| US-6232338-B1 | 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors | ZENECA LIMITED (GB) | 2001-05-15 | — | — | US | disclosed |
| EP-0611115-B1 | Preparation of beta-lactam compounds, and intermediates therefor | SHIONOGI & CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| EP-1051416-A1 | 1,4-DIAZACYCLOHEPTANE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | AstraZeneca UK Limited (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000056738-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| EP-0673947-B1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | SANKYO CO (JP) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000039716-A2 | ARYLPROPENYLIMIDAZOLES AS FARNESYL-PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |
| US-6069145-A | AGAINST ANTIBIOTIC RESISTANT BACTERIA | ZENECA LIMITED (GB) | 2000-05-30 | — | — | US | disclosed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000015657-A1 | PIPERIZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND 53 | ASTRAZENECA AB (SE) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000012467-A1 | N-HYDROXYACYLAMINO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0971881-A1 | PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0971895-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | AstraZeneca AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999038863-A1 | 1,4-DIAZACYCLOHEPTANE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ASTRAZENECA UK LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |
| EP-0923545-A1 | 3-MERCAPTOPYRROLIDINES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-06-23 | — | — | EP | disclosed |
| EP-0912561-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0907653-A1 | PROCESS FOR THE PREPARATION OF PENAM AND PENEM DERIVATIVES | ZENECA LIMITED (GB) | 1999-04-14 | — | — | EP | disclosed |
| EP-0906312-A1 | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| EP-0892795-A1 | PIPERIDINYLPYRAMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-01-27 | — | — | EP | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0882041-A1 | PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998043959-A1 | HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998043946-A1 | PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998035982-A1 | COMPOUNDS FOR USE IN ADEPT | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
| EP-0842151-A1 | 4-MERCAPTOPYRROLIDINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998007742-A1 | SULFONAMIDES | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| WO-1998007692-A1 | 3-MERCAPTOPYRROLIDINES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| US-5719139-A | BACTERICIDES | ZENECA LIMITED (GB) | 1998-02-17 | — | — | US | disclosed |
| WO-1998000429-A1 | PROCESS FOR THE PREPARATION OF PENAM AND PENEM DERIVATIVES | ZENECA LIMITED (GB) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997047621-A1 | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997042168-A1 | THIO DERIVATIVES OF HYDROXAMIC ACIDS | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997038992-A1 | PIPERIDINYLPYRAMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997027188-A1 | PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-07-31 | — | — | WO | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| EP-0421440-B1 | Process for producing azetidinone derivatives | MERCIAN CORP (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5607928-A | Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives | ZENECA LIMITED (GB) | 1997-03-04 | — | — | US | disclosed |
| WO-1997006138-A1 | 4-MERCAPTOPYRROLIDINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| JP-H08325281-A | PRODUCTION OF OPTICALLY ACTIVE ALPHA-AMINOPHOSPHONIC ACID DERIVATIVE AND CATALYST FOR ASYMMETRIC SYNTHESIS AND NEW PHOSPHONATE-BASED COMPOUND | HOKKO CHEM IND CO LTD | 1996-12-10 | — | — | JP | disclosed |
| US-5580976-A | AZETIDINONE CHEMICAL INTERMEDIATE, USEFUL FOR PREPARING ANTIBIOTICS | SHIONOGI & CO., LTD. (JP) | 1996-12-03 | — | — | US | disclosed |
| US-5571805-A | FOR TREATING BACTERIAL INFECTIONS IN MAMMALS | ZENECA LIMITED (GB) | 1996-11-05 | — | — | US | disclosed |
| US-5563264-A | Preparation of βlactam compounds | SHIONOGI & CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5554606-A | THIENAMYCIN DERIVATIVES; PSEUDOMONAS | ZENECA LIMITED (GB) | 1996-09-10 | — | — | US | disclosed |
| US-5541178-A | THIENAMYCINS | ZENECA LIMITED (GB) | 1996-07-30 | — | — | US | disclosed |
| US-5538962-A | PENICILLINS | ZENECA LIMITED (GB) | 1996-07-23 | — | — | US | disclosed |
| US-5527791-A | Carbapenem antibiotic compounds | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| US-5527793-A | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| US-5519015-A | BACTERICIDES | ZENECA LIMITED (GB) | 1996-05-21 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0673947-A1 | PSICOFURANOSE AND PSICOPYRANOSE DERIVATIVES | Sankyo Company Limited (JP) | 1995-09-27 | — | — | EP | disclosed |
| US-5447925-A | Carbapenems with side-chain S; use to treat infections | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-09-05 | — | — | US | disclosed |
| US-5444057-A | FOR TREATING BACTERIAL INFECTIONS | ZENECA LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| US-5441949-A | Carbapenem antibiotic compounds | ZENECA LIMITED (GB) | 1995-08-15 | — | — | US | disclosed |
| US-5424422-A | Beta-lactams and their production | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5412093-A | 3-heterocyclic thiomethyl cephalosporins | ICI PHARMA (FR) | 1995-05-02 | — | — | US | disclosed |
| EP-0126587-B1 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | SUMITOMO PHARMA (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5371220-A | Bicyclo-heterocyclic intermediates for cephalosporin compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-06 | — | — | US | disclosed |
| EP-0611115-A1 | Preparation of beta-lactam compounds, and intermediates therefor | SHIONOGI & CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0229384-B1 | Beta-lactam compounds and their production | SUMITOMO PHARMA (JP) | 1994-08-10 | — | — | EP | disclosed |
| US-5310897-A | Beta-lactams and their production | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1994-05-10 | — | — | US | disclosed |
| EP-0584085-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LIMITED (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0580632-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0581502-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0581500-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0581501-A1 | Antibiotic carbapenem compounds | ZENECA LIMITED (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0331146-B1 | Process for preparation of beta-lactam derivatives | OTSUKA KAGAKU KK (JP) | 1994-01-12 | — | — | EP | disclosed |
| US-5262410-A | Antibiotics | ICI PHARMA (FR) | 1993-11-16 | — | — | US | disclosed |
| US-5232918-A | Bactericides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5219848-A | Bactericides | ICI PHARMA (FR) | 1993-06-15 | — | — | US | disclosed |
| US-5200404-A | Bactericides | ICI PHARMA (FR) | 1993-04-06 | — | — | US | disclosed |
| WO-1992017479-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992017480-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992017481-A1 | ANTIBIOTIC CARBAPENEM DERIVATIVES | ZENECA LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
| US-5149803-A | Intermediates for cephalosporin compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-09-22 | — | — | US | disclosed |
| US-5149802-A | Chemical intermediates for antibiotics | MERCIAN CORPORATION (JP) | 1992-09-22 | — | — | US | disclosed |
| US-5134231-A | Chemical intermediates for 1-alkylcarbapenem compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-28 | — | — | US | disclosed |
| EP-0243686-B1 | BETA-LACTAM COMPOUNDS, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-5126444-A | Antibiotics | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5122604-A | 2-(2-Carbonyl-substituted pyrrolidin-4-yl)carbapenems and -penems; microbiocides | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| US-5114933-A | Bactericides | ICI PHARMA (FR) | 1992-05-19 | — | — | US | disclosed |
| US-5112966-A | Intermediates for carbapenicillins | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-05-12 | — | — | US | disclosed |
| US-5093328-A | Carbapenicillin antibiotics | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5075435-A | Chemical intermediates for 1-methylcarbapenicillin | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| US-5064824-A | CEPHALOSPORIN COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-12 | — | — | US | disclosed |
| US-5057511-A | Antibiotics, bactericides | ICI PHARMA (GB) | 1991-10-15 | — | — | US | disclosed |
| US-5055462-A | CEPHALOSPORIN COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-08 | — | — | US | disclosed |
| US-5053500-A | INTERMEDIATES FOR THE PREPARATION OF BETA-LACTAM ANTIBIOTICS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-01 | — | — | US | disclosed |
| US-5019570-A | Antibioics | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-05-28 | — | — | US | disclosed |
| US-5017569-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1991-05-21 | — | — | US | disclosed |
| US-5013730-A | Antibiotics | ICI-PHARMA (FR) | 1991-05-07 | — | — | US | disclosed |
| US-5008259-A | Antibiotics active against strains of Pseudomonas and stable to beta-lactamase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-16 | — | — | US | disclosed |
| US-5008258-A | Antibiotics | I.C.I.-PHARMA (FR) | 1991-04-16 | — | — | US | disclosed |
| EP-0421440-A2 | Process for producing azetidinone derivatives | MERCIAN CORPORATION (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0188816-B1 | NOVEL BETA-LACTAMS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-10-17 | — | — | EP | disclosed |
| US-4943569-A | B-lactam compounds | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1990-07-24 | — | — | US | disclosed |
| US-4940788-A | Process for preparing azetidinones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-10 | — | — | US | disclosed |
| US-4939250-A | Process for preparation of β-lactam derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-03 | — | — | US | disclosed |
| US-4933333-A | β-lactam compounds | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4925934-A | DEESTERIFICATION | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1990-05-15 | — | — | US | disclosed |
| US-4892961-A | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0331146-A1 | Process for preparation of beta-lactam derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1989-09-06 | — | — | EP | disclosed |
| EP-0210657-B1 | AMINO ACID DERIVATIVES, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0304158-A1 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | disclosed |
| EP-0271586-A1 | $g(b)-LACTAM COMPOUNDS AND PROCESS FOR THEIR PREPARATION | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1988-06-22 | — | — | EP | disclosed |
| WO-1988001619-A1 | 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-10 | — | — | WO | disclosed |
| EP-0106652-B1 | BETA-LACTAM COMPOUNDS AND PRODUCTION THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-01-27 | — | — | EP | disclosed |
| EP-0243686-A2 | Beta-lactam compounds, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-04 | — | — | EP | disclosed |
| EP-0229384-A2 | Beta-lactam compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0224385-A2 | Intermediates for the preparation of beta-lactam antibiotics | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-03 | — | — | EP | disclosed |
| EP-0223588-A1 | Process for the preparation of beta-lactam compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-27 | — | — | EP | disclosed |
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0180189-A2 | Novel beta-lactams and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4556514-A | INTERMEDIATES FOR PRODUCTION OF CARBAPENEM OR PENEM DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-03 | — | — | US | disclosed |
| EP-0160910-A2 | 7-Deazapurine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1985-11-13 | — | — | EP | disclosed |
| EP-0126587-A1 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-11-28 | — | — | EP | disclosed |
| EP-0106652-A1 | Beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
| EP-0106652-A1 | Beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | ALDH1A1 392/4885ALOX15 1174/4885TP53 1320/4885 |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | ALDH1A1 165/4885ALOX15 1065/4885TP53 2451/4885 |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | ALDH1A1 3433/4885ALOX15 78/4885TP53 4835/4885 |
| US-20090018157-A1 | Chemical compounds | GALK1, GCK, GRK1 | ALDH1A1 1671/4885ALOX15 3057/4885TP53 4263/4885 |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | ALDH1A1 293/4885ALOX15 1267/4885TP53 2011/4885 |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | ALDH1A1 2501/4885ALOX15 2800/4885TP53 4789/4885 |
| US-20040138104-A1 | Peptides | PTMS, VIP, CPB1 | ALDH1A1 4239/4885ALOX15 2435/4885TP53 1848/4885 |
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | ALDH1A1 2771/4885ALOX15 2965/4885TP53 165/4885 |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | F12, XDH, REN | ALDH1A1 1971/4885ALOX15 4438/4885TP53 4271/4885 |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | ALDH1A1 1984/4885ALOX15 3478/4885TP53 4451/4885 |
| US-20080146566-A1 | Amide Derivatives | IL6, IL1B, IL1A | ALDH1A1 327/4885ALOX15 1088/4885TP53 2280/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | ALDH1A1 1116/4885ALOX15 43/4885TP53 4788/4885 |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | ALDH1A1 337/4885ALOX15 2463/4885TP53 3605/4885 |
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | ALDH1A1 264/4885ALOX15 1206/4885TP53 1824/4885 |
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | ALDH1A1 3269/4885ALOX15 2643/4885TP53 4140/4885 |
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | ALDH1A1 269/4885ALOX15 416/4885TP53 2400/4885 |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | ALDH1A1 628/4885ALOX15 13/4885TP53 4373/4885 |
| US-20020040002-A1 | Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor | MMP1, HCAR1, MMP13 | ALDH1A1 618/4885ALOX15 100/4885TP53 1272/4885 |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | F7, SERPINE1, HABP2 | ALDH1A1 3767/4885ALOX15 3764/4885TP53 2895/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | ALDH1A1 269/4885ALOX15 416/4885TP53 2400/4885 |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | GCK, GCKR, GRK4 | ALDH1A1 2707/4885ALOX15 557/4885TP53 4831/4885 |
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | ALDH1A1 1137/4885ALOX15 2968/4885TP53 4054/4885 |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, GCKR, GALK1 | ALDH1A1 958/4885ALOX15 2932/4885TP53 3236/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ALDH1A1 1382/4885ALOX15 2881/4885TP53 4749/4885 |
| US-20030083348-A1 | Farnesyl transferase inhibitors | FNTA, FNTB, FDPS | ALDH1A1 654/4885ALOX15 1042/4885TP53 498/4885 |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | ALDH1A1 3361/4885ALOX15 90/4885TP53 4847/4885 |
| US-20070255062-A1 | Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators | GCK, GALK1, PDXK | ALDH1A1 1329/4885ALOX15 2503/4885TP53 4096/4885 |
| US-20080318968-A1 | Chemical Compounds | GCKR, GCK, HK1 | ALDH1A1 836/4885ALOX15 30/4885TP53 4522/4885 |
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | ALDH1A1 1425/4885ALOX15 2422/4885TP53 4763/4885 |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALDH1A1 1072/4885ALOX15 4253/4885TP53 342/4885 |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | ALDH1A1 262/4885ALOX15 357/4885TP53 3235/4885 |
| US-20030105142-A1 | Amide derivatives useful as inhibitors of the production of cytokines | IL6, IL6ST, IL2 | ALDH1A1 278/4885ALOX15 613/4885TP53 1874/4885 |
| US-20030186966-A1 | Amide derivatives | IL6, IL6ST, IFNG | ALDH1A1 353/4885ALOX15 703/4885TP53 2979/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | ALDH1A1 1918/4885ALOX15 1914/4885TP53 4297/4885 |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | ALDH1A1 361/4885ALOX15 939/4885TP53 1312/4885 |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | GCK, GCKR, HK1 | ALDH1A1 862/4885ALOX15 51/4885TP53 4719/4885 |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | ALDH1A1 1486/4885ALOX15 3536/4885TP53 4561/4885 |
| US-20080234273-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, HK1 | ALDH1A1 866/4885ALOX15 88/4885TP53 4678/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | ALDH1A1 1016/4885ALOX15 4256/4885TP53 300/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | ALDH1A1 1116/4885ALOX15 43/4885TP53 4788/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ALDH1A1 1579/4885ALOX15 2909/4885TP53 4658/4885 |
| US-20050209217-A1 | 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors | FNTB, FNTA, KRAS | ALDH1A1 1024/4885ALOX15 3952/4885TP53 134/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | ALDH1A1 1137/4885ALOX15 2968/4885TP53 4054/4885 |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | ALDH1A1 2601/4885ALOX15 4319/4885TP53 4053/4885 |
| US-20070093535-A1 | Vinyl phenyl derivatives as GLK activators | GCK, GCKR, GK | ALDH1A1 1641/4885ALOX15 1962/4885TP53 3656/4885 |
| US-20030096842-A1 | Inhibitors of farnesyl protein transferase | FNTA, FNTB, FDPS | ALDH1A1 1338/4885ALOX15 1620/4885TP53 487/4885 |
| US-20150246931-A1 | PROCESS FOR THE PREPARATION OF TAZOBACTAM | FDPS, BPGM, MPST | ALDH1A1 2307/4885ALOX15 1175/4885TP53 4488/4885 |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | ALDH1A1 361/4885ALOX15 939/4885TP53 1312/4885 |
| US-20090062351-A1 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators | GCK, GCKR, GALK1 | ALDH1A1 1756/4885ALOX15 3410/4885TP53 4132/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | ALDH1A1 1137/4885ALOX15 2968/4885TP53 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.